How did APYX's revenue and expenses shift in Q4 2024 compared to previous quarters?

**Apyx Medical Corporation (APYX) experienced a decline in revenue and an increase in expenses in Q4 2024 compared to the previous quarter, Q3 2024**: 1. **Revenue Shift**: - Apyx Medical's total revenue for Q4 2024 was $14.22 million. - In Q3 2024, the revenue was $11.49 million. - In Q2 2024, the revenue was $12.15 million. - In Q1 2024, the revenue was $10.24 million. - This indicates a seasonal trend with higher revenues in Q2 and Q4, possibly due to increased surgical procedures in these quarters. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |APYX|APYX.O|Apyx Medical|2023 Q4|16.263579414796606|1.4662E7|185| |APYX|APYX.O|Apyx Medical|2024 Q1|-15.631691648822269|1.0244E7|185| |APYX|APYX.O|Apyx Medical|2024 Q2|-10.46503058442037|1.2149E7|185| |APYX|APYX.O|Apyx Medical|2024 Q3|-4.08316633266533|1.1487E7|185| 2. **Expense Shift**: - No specific data on APYX's expenses in Q4 2024 is available. - However, the company reported a gross profit decrease to $7 million and a gross margin of 60.5% in Q3 2024, which could imply cost management challenges. - Operating expenses dropped to $10.6 million in Q3 2024, indicating a potential reduction in operational costs. 3. **Financial Performance**: - Apyx Medical reported a quarterly adjusted loss of 12 cents per share for Q4 2024, which was worse than the same quarter last year and exceeded analysts' expectations. - The company's net loss attributable to shareholders was $4.7 million, or $0.14 per share, for Q3 2024. - The earnings per share (EPS) for Q4 2024 was -$0.12, which was a deterioration from the previous quarter's -$0.14. 4. **Market Challenges**: - Apyx Medical faces a challenging landscape due to economic headwinds and a difficult environment in the cosmetic surgery sector. - The company's Advanced Energy division, which includes its flagship Renuvion product, has experienced a significant decline in sales. - Despite these challenges, there are positive points, such as growth in disposable handpiece revenues and strong demand for consumable products. In conclusion, Apyx Medical has shown a seasonal increase in revenue in Q4 2024, but faced challenges in managing expenses and maintaining profitability amidst a difficult market environment.